SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacopsychiatry

• Publication date

  2014-10-08

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1055/s-0035-1545318PMID 25738265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

  2014cited by this paper
• Polymorphisms in Serotonergic Pathways Influence the Outcome of Antidepressant Therapy in Psychiatric Inpatients

  2014cited by this paper
• Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response.

  2014cited by this paper
• SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome

  2014cited by this paper
• Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health's Collaborative Center for Genomic Studies

  2013cited by this paper
• The clinical global impression scale and the influence of patient or staff perspective on outcome

  2011cited by this paper
• The Serotonin Transporter Promoter Polymorphism (5-HTTLPR) Affects the Relation between Antidepressant Serum Concentrations and Effectiveness in Major Depression

  2011cited by this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cited by this paper
• Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.

  2010cited by this paper
• Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression

  2010cited by this paper
• Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder

  2010cited by this paper
• Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.

  2010cited by this paper
• Serotonin Transporter Gene Polymorphism Associated with Short-Term Treatment Response to Venlafaxine

  2010cited by this paper
• Association studies of −3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population

  2010cited by this paper
• Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

  2009cited by this paper
• An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder

  2009cited by this paper
• SLC6A4 variation and citalopram response

  2009cited by this paper
• Serotonin Transporter Gene Polymorphisms and Sertraline Response in Major Depression Patients

  2008cited by this paper
• Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder

  2008cited by this paper
• Differential physiological effects of a low dose and high doses of venlafaxine in major depression.

  2007cited by this paper
• Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

  2006cited by this paper
• Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531

  2006cited by this paper
• Sequence analysis of the serotonin transporter and associations with antidepressant response.

  2005cited by this paper
• The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

  2004cited by this paper
• 5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study

  2003cited by this paper
• Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

  2003cited by this paper
• Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.

  2002cited by this paper
• Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

  2001cited by this paper
• The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants

  2000cited by this paper
• Evidence of the dual mechanisms of action of venlafaxine.

  2000cited by this paper
• Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene.

  2000cited by this paper
• Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

  1998cited by this paper
• Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching.

  1996cited by this paper
• Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region

  1996cited by this paper
• Allelic Variation of Human Serotonin Transporter Gene Expression

  1996cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• A simple salting out procedure for extracting DNA from human nucleated cells.

  1988cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper

• [Therapeutic drug monitoring of antidepressants: Why venlafaxine is the most monitored drug? A review of literature].

  2021cites this paper
• Associations of the serotonin transporter promoter polymorphism (5‐HTTLPR) with bipolar disorder and treatment response: A systematic review and meta‐analysis

  2019cites this paper
• Genetic Factors Underlying Treatment Resistance in Psychiatry

  2018cites this paper
• Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies

  2016cites this paper